Ziyu Meng

Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice

Zhe Han, Bei Sun, Li-ming Chen, 2020, International journal of biological sciences.

Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway

Bei Sun, Mei Xue, Xiaoyu Li, 2022, Frontiers in Physiology.

A prospective diagnostic and prognostic biomarker for hepatocellular carcinoma that functions in glucose metabolism regulation: Solute carrier family 37 member 3.

Xiaoyue Lin, Ying Zhu, Dan-Ming Chen, 2023, Biochimica et biophysica acta. Molecular basis of disease.

The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.

Liping Han, Liming Chen, Bei Sun, 2021, International immunopharmacology.

Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes

Liming Chen, Bei Sun, Mei Xue, 2019, Diabetologia.